NKGen Biotech (NKGN) announced the successful completion of its acquisition of a majority equity stake in NKMax, a Korean biotechnology company, out of bankruptcy. “This acquisition marks a transformative step for NKGen, granting full control over key global manufacturing infrastructure, intellectual property and exclusive commercialization rights, while solidifying the Company’s position as an independent and vertically integrated leader in NK cell therapeutics,” the company said.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKGN:
- NKGen Biotech presents troculeucel mechanism of action
- NKGen Biotech announces FDA granted EAP authorization for IND of troculeucel
- NKGen Biotech Partners with HekaBio for SNK01 in Japan
- NKGen Biotech, HekaBio enter strategic partnership to bring troculeucel to Japan
- NKGen Biotech Secures Funding Amid Compliance Challenges